Across adult and adolescent populations, both with and without comorbidities such as type 2 diabetes or cardiovascular disease, GLP-1 RAs have led to notable reductions in body weight and improvements in metabolic parameters. This evidence concerns the gene GCG and cardiovascular disorder.